Our Focus on the Future Present
By Jacob Corn,
Innovative Genomics Initiative blog
| 07. 06. 2015
Untitled Document
It’s been a rather wild ride in the last month, which hasn’t left much time for blog posts. But I’m planning to turn over a new leaf and start posting at least something short at the beginning of every week.
This week’s post addresses a question that I’ve been asked in many ways by many people: what about germline editing? After the IGI started the ball rolling with a small meeting in Napa, we penned a call for a temporary moratorium on germline editing and have been lobbying for a larger summit, which is now slated for October. I think it likely that restriction or proscription of germline editing will be the outcome.
At this time, the IGI Lab will not do research on human germline editing for several reasons, including:
1. The IGI Lab is focusing on diseases for which somatic (non-heritable) editing would be a transformative advance. The media loves to talk about designer babies, but we actually don’t know the first thing about the genetic basis behind complex traits like beauty of intelligence. But we do know a lot about genetic disease, particularly so-called monogenic disorders, in which a problem in a...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...